



## PRESS RELEASE

### **GENFIT: Third quarter 2018 financial information**

*(Unaudited financial information under IFRS)*

- **Cash and cash equivalents of €219.9 million at September 30, 2018**
- **Revenues for the first nine months of 2018 of €68 thousand**

**Lille (France), Cambridge (Massachusetts, United States), October 23, 2018** – GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases today announces its cash position at September 30, 2018 and its revenues for the first nine months of 2018.

#### **Cash position**

At September 30, 2018, the Company's cash and cash equivalents amounted to €219.9 million compared with €113.8 million one year earlier.

At June 30, 2018, cash and cash equivalents totaled €238 million.

#### **Revenues**

Revenues for the first nine months of 2018 amounted to €68 thousand compared to €91 thousand for the same period in 2017.

#### **ABOUT GENFIT**

GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases. GENFIT's concentrates its R&D efforts in areas of high unmet medical needs corresponding to a lack of approved treatments. GENFIT's lead proprietary compound, elafibanor, is a drug candidate currently being evaluated in one of the most advanced Phase 3 studies worldwide ("RESOLVE-IT") in nonalcoholic steatohepatitis (NASH), considered by regulatory authorities as a medical emergency because it is silent, with potentially severe consequences, and with a prevalence on the rise. It is also evaluated in a Phase 2 study in Primary Biliary Cholangitis (PBC), a rare liver disease. As part of its comprehensive approach to clinical management of NASH patients, GENFIT is conducting an ambitious discovery and development program aimed at providing patients and physicians with a blood-based test for the diagnosis of NASH, i.e. non-invasive and easy-to-access. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 140 employees. GENFIT is a public company listed in



## PRESS RELEASE

compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111).  
[www.genfit.com](http://www.genfit.com)

### **FORWARD LOOKING STATEMENT / DISCLAIMER**

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to biomarkers, progression of, and results of clinical data from, the RESOLVE-IT trial and the trial of elafibranor in PBC, review and approvals by regulatory authorities, such as the FDA or the EMA, regarding in particular, elafibranor in NASH and PBC, as well as other drug candidates in other indications and biomarkers candidates, the success of any inlicensing strategies, the Company's continued ability to raise capital to fund its development, as well as those discussed or identified in the Company's public filings with the AMF, including those listed in Section 4 "Main Risks and Uncertainties" of the Company's 2017 Registration Document registered with the French Autorité des marchés financiers on April 27, 2018 under n° R.18-032, which is available on GENFIT's website ([www.genfit.com](http://www.genfit.com)) and on the website of the AMF ([www.amf-france.org](http://www.amf-france.org)) and updated by its 2018 Half Year Business and Financial Report available on the "Investors" page of its website. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

### **CONTACT**

**GENFIT** | Jean-François Mouney – Chairman & CEO | +333 2016 4000

**PRESS RELATIONS** | Bruno Arabian – Ulysse Communication | +336 8788 4726